Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D Berkowitz

Showing results (451-460 of 497) with videos related to

Pageof 50
Sort By:
Stroke|April 19, 2014
Intracranial hemorrhage among patients with atrial fibrillation anticoagulated with warfarin or rivaroxaban: the rivaroxaban once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillationGraeme J Hankey, Susanna R Stevens, Jonathan P Piccini, et al.
BMJ Open|October 12, 2022
COVID-19 susceptibility and severity risks in a cross-sectional survey of over 500 000 US adultsSpencer C Knight, Shannon R McCurdy, Brooke Rhead, et al.
Circulation|November 3, 2020
Rivaroxaban and Aspirin in Peripheral Artery Disease Lower Extremity Revascularization: Impact of Concomitant Clopidogrel on Efficacy and SafetyWilliam R Hiatt, Marc P Bonaca, Manesh R Patel, et al.
International Journal of Cardiology|March 7, 2018
Net clinical benefit of rivaroxaban compared with warfarin in atrial fibrillation: Results from ROCKET AFAdam S Barnett, Derek D Cyr, Shaun G Goodman, et al.
Heart Rhythm|May 17, 2014
Use and outcomes of antiarrhythmic therapy in patients with atrial fibrillation receiving oral anticoagulation: results from the ROCKET AF trialBenjamin A Steinberg, Anne S Hellkamp, Yuliya Lokhnygina, et al.
European Heart Journal|August 24, 2014
Clinical characteristics and outcomes with rivaroxaban vs. warfarin in patients with non-valvular atrial fibrillation but underlying native mitral and aortic valve disease participating in the ROCKET AF trialGünter Breithardt, Helmut Baumgartner, Scott D Berkowitz, et al.
Journal of the American College of Cardiology|September 21, 2019
Major Bleeding in Patients With Coronary or Peripheral Artery Disease Treated With Rivaroxaban Plus AspirinJohn W Eikelboom, Jacqueline J Bosch, Stuart J Connolly, et al.
Stroke|August 13, 2019
Efficacy and Safety of Rivaroxaban Versus Aspirin in Embolic Stroke of Undetermined Source and Carotid AtherosclerosisGeorge Ntaios, Balakumar Swaminathan, Scott D Berkowitz, et al.
Journal of the American College of Cardiology|June 17, 1998
Modifiable risk factors for vascular access site complications in the IMPACT II Trial of angioplasty with versus without eptifibatide. Integrilin to Minimize Platelet Aggregation and Coronary ThrombosisJ S Mandak, J C Blankenship, L H Gardner, et al.
Annals of the New York Academy of Sciences|May 25, 2013
Rivaroxaban: a novel oral anticoagulant for the prevention and treatment of several thrombosis-mediated conditionsTroy C Sarich, Gary Peters, Scott D Berkowitz, et al.
Pageof 50

Showing results (451-460 of 497) with videos related to

Sort By:
Pageof 50
Stroke|April 19, 2014
Intracranial hemorrhage among patients with atrial fibrillation anticoagulated with warfarin or rivaroxaban: the rivaroxaban once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillationGraeme J Hankey, Susanna R Stevens, Jonathan P Piccini, et al.
BMJ Open|October 12, 2022
COVID-19 susceptibility and severity risks in a cross-sectional survey of over 500 000 US adultsSpencer C Knight, Shannon R McCurdy, Brooke Rhead, et al.
Circulation|November 3, 2020
Rivaroxaban and Aspirin in Peripheral Artery Disease Lower Extremity Revascularization: Impact of Concomitant Clopidogrel on Efficacy and SafetyWilliam R Hiatt, Marc P Bonaca, Manesh R Patel, et al.
International Journal of Cardiology|March 7, 2018
Net clinical benefit of rivaroxaban compared with warfarin in atrial fibrillation: Results from ROCKET AFAdam S Barnett, Derek D Cyr, Shaun G Goodman, et al.
Heart Rhythm|May 17, 2014
Use and outcomes of antiarrhythmic therapy in patients with atrial fibrillation receiving oral anticoagulation: results from the ROCKET AF trialBenjamin A Steinberg, Anne S Hellkamp, Yuliya Lokhnygina, et al.
European Heart Journal|August 24, 2014
Clinical characteristics and outcomes with rivaroxaban vs. warfarin in patients with non-valvular atrial fibrillation but underlying native mitral and aortic valve disease participating in the ROCKET AF trialGünter Breithardt, Helmut Baumgartner, Scott D Berkowitz, et al.
Journal of the American College of Cardiology|September 21, 2019
Major Bleeding in Patients With Coronary or Peripheral Artery Disease Treated With Rivaroxaban Plus AspirinJohn W Eikelboom, Jacqueline J Bosch, Stuart J Connolly, et al.
Stroke|August 13, 2019
Efficacy and Safety of Rivaroxaban Versus Aspirin in Embolic Stroke of Undetermined Source and Carotid AtherosclerosisGeorge Ntaios, Balakumar Swaminathan, Scott D Berkowitz, et al.
Journal of the American College of Cardiology|June 17, 1998
Modifiable risk factors for vascular access site complications in the IMPACT II Trial of angioplasty with versus without eptifibatide. Integrilin to Minimize Platelet Aggregation and Coronary ThrombosisJ S Mandak, J C Blankenship, L H Gardner, et al.
Annals of the New York Academy of Sciences|May 25, 2013
Rivaroxaban: a novel oral anticoagulant for the prevention and treatment of several thrombosis-mediated conditionsTroy C Sarich, Gary Peters, Scott D Berkowitz, et al.
Pageof 50